Verve Therapeutics (VERV)
(Real Time Quote from BATS)
$5.55 USD
-0.07 (-1.25%)
Updated Sep 10, 2024 12:48 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Verve Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 624 | 555 | 360 | 72 | 0 |
Receivables | 6 | 1 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 8 | 7 | 7 | 2 | 0 |
Total Current Assets | 638 | 563 | 367 | 74 | 0 |
Net Property & Equipment | 23 | 19 | 7 | 4 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 7 | 5 | 8 | 0 | 0 |
Total Assets | 753 | 679 | 384 | 78 | 0 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 2 | 7 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 20 | 21 | 13 | 7 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 37 | 35 | 22 | 7 | 0 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 49 | 20 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3 | 3 | 5 | 10 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 125 | 0 |
Total Liabilities | 153 | 128 | 27 | 142 | 0 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,143 | 896 | 544 | 3 | 0 |
Retained Earnings | -544 | -344 | -187 | -67 | 0 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 600 | 551 | 357 | -64 | 0 |
Total Liabilities & Shareholder's Equity | 753 | 679 | 384 | 78 | 0 |
Total Common Equity | 600 | 551 | 357 | -64 | 0 |
Shares Outstanding | 81.90 | 61.60 | 48.10 | NA | NA |
Book Value Per Share | 7.32 | 8.94 | 7.43 | 0.00 | 0.00 |
Fiscal Year End for Verve Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 576 | 606 | 624 | 485 | 462 |
Receivables | 3 | 6 | 6 | 3 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 12 | 8 | 8 | 10 | 9 |
Total Current Assets | 591 | 620 | 638 | 498 | 473 |
Net Property & Equipment | 20 | 21 | 23 | 21 | 21 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 8 | 7 | 7 | 6 | 6 |
Total Assets | 701 | 732 | 753 | 612 | 589 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 3 | 7 | 1 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 20 | 17 | 20 | 23 | 20 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3 | 1 | 0 | 0 | 0 |
Total Current Liabilities | 40 | 31 | 37 | 35 | 33 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 51 | 52 | 49 | 49 | 20 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 3 | 2 | 3 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 155 | 149 | 153 | 152 | 124 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,189 | 1,177 | 1,143 | 957 | 916 |
Retained Earnings | -643 | -593 | -544 | -496 | -450 |
Other Equity | -1 | -1 | 0 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 546 | 583 | 600 | 460 | 465 |
Total Liabilities & Shareholder's Equity | 701 | 732 | 753 | 612 | 589 |
Total Common Equity | 546 | 583 | 600 | 460 | 465 |
Shares Outstanding | 83.90 | 83.90 | 81.90 | 63.70 | 61.90 |
Book Value Per Share | 6.51 | 6.95 | 7.32 | 7.23 | 7.52 |